Cancer therapy using tumor-associated antigens to reduce side effects.
Tumor-associated antigens recently have become very popular in cancer therapy. They can be targeted to reduce side effects of traditional cancer therapy. In this review, ten promising tumor-associated antigens are being discussed in detail. The characteristics of each one are being reviewed in detail. Monoclonal antibodies attached to traditional anticancer agents can target a specific type of cancer cells thereby reducing the amount of traditional anticancer agents reaching normal tissues. This sort of cancer targeting can be a very attractive anticancer therapy because it substantially reduces the amount of side effects normally caused by traditional anticancer agents.
Siu
David
D
Department of Obstetrics and Gynaecology, British Columbia Research Institute for Children's and Women's Health, University of British Columbia, Vancouver, BC, V5R 5K6, Canada. dkcsiu@interchange.ubc.ca
D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D000922:Immunotoxins / Q000494:pharmacology* / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D000922:Immunotoxins